AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36335552
Drug: Medicinal cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicinal cannabis (MC) as a prescription-only medication
Trial: 35302210
Drug: Ketamine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2.0 mg/kg (K2 group)
Trial: 36193903
Drug: 12-week tele-exercise
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week tele-exercise training program (3 sessions/week, 30 min/session, weekly remote monitoring)
Trial: 34032504
Drug: Intermittent Androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Androgen Deprivation Therapy (IADT)
Trial: 36067985
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (education on nutrition, oral hygiene, and child stimulation)
Trial: 35775631
Drug: Curcumin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin treatment (200 mg twice daily for 6 weeks)
Trial: 35775631
Drug: Curcumin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin treatment
Trial: 35446936
Drug: Eltrombopag (ELTR)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag (ELTR) combined with immunosuppressive therapy (IST)
Trial: 35446936
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy (IST) alone
Trial: 35446936
Drug: Eltrombopag (ELTR)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag (ELTR) combined with immunosuppressive therapy (IST) in SAA
Trial: 35446936
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy (IST) alone in SAA
Trial: 35446936
Drug: Eltrombopag (ELTR)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag (ELTR) combined with immunosuppressive therapy (IST) in vSAA
Trial: 35446936
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy (IST) alone in vSAA
Trial: 33462752
Drug: Entrectinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrectinib (600 mg research formulation)
Trial: 33462752
Drug: Entrectinib (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrectinib (100-400 mg/m2, and 600-800 mg) once daily with food
Trial: 33462752
Drug: Entrectinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrectinib (600 mg single doses, fasted state)
Trial: 32460816
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy (NET) with goserelin and tamoxifen for 24 weeks
Trial: 33681738
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg
Trial: 34782125
Drug: Population-wide metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Population-wide metformin therapy
Trial: 37266947
Drug: Low-Molecular-Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Molecular-Weight Heparin (LMWH)
Trial: 33156289
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UH)
Trial: 37271356
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (OMT) alone
Trial: 34053111
Drug: Cracked corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cracked corn (CC: 74% NSC & 9% CP)
Trial: 34053111
Drug: Low NSC
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NSC pellet (L-NSC: 6% NSC & 12% CP)
Trial: 33002071
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP target < 140 mmHg)
Trial: 32216011
Drug: Vericiguat 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat 10.0 mg
Trial: 35818134
Drug: TAC/Collagen gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC/Collagen gel
Trial: 34428980
Drug: BGF 320/18/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 320/18/9.6 µg
Trial: 34428980
Drug: BGF 160/18/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 160/18/9.6 µg
Trial: 34428980
Drug: GFF 18/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF 18/9.6 µg
Trial: 34428980
Drug: BFF 320/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFF 320/9.6 µg
Trial: 32444980
Drug: FSRS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSRS plus BEV-based chemotherapy
Trial: 32444980
Drug: BEV-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEV-based chemotherapy alone
Trial: 32781457
Drug: 2.5‐mg hypobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5‐mg hypobaric bupivacaine alone
Trial: 32781457
Drug: 2.5‐mg hypobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5‐mg hypobaric bupivacaine and 10‐μg fentanyl
Trial: 32781457
Drug: 2.5‐mg hypobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5‐mg hypobaric bupivacaine and 0.5‐mg morphine
Trial: 32048900
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% ointment plus PSD
Trial: 32994242
Drug: Metformin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (various dosages)
Trial: 34207870
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 gr, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Trial: 34207870
Drug: Tailored therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored therapy based on antimicrobial susceptibility testing
Trial: 33039650
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU vitamin E and/or 20 μg selenium daily
Trial: 37318667
Drug: 650 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 nm low-level red light (LLRL) irradiation for 6 min daily
Trial: 34716791
Drug: High polyphenol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High polyphenol olive oil (HPOO) 60 mL/day (320 mg/kg polyphenols)
Trial: 34716791
Drug: Low polyphenol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low polyphenol olive oil (LPOO) 60 mL/day (86 mg/kg polyphenols)
Trial: 35107389
Drug: Standard antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiviral therapy
Trial: 34714720
Drug: Quadrivalent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent high-dose inactivated influenza vaccine (IIV4-HD)
Trial: 34714720
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (IIV4-HD and IIV4-SD)
Trial: 33473017
Drug: Standard supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supportive treatment
Trial: 35699175
Drug: Genotype-guided selection
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided selection of antiplatelet therapy after PCI
Trial: 35699175
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with clopidogrel
Trial: 33450486
Drug: Intermittent low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermittent low-dose esomeprazole (40 mg once a day for 8 weeks)
Trial: 33450486
Drug: Continuous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-dose esomeprazole (40 mg once a day for 8 weeks)
Trial: 33450486
Drug: Continuous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-dose esomeprazole
Trial: 34377044
Drug: TDT 064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDT 064 (topical agent)
Trial: 34321051
Drug: Short-term mentalisation-based
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term mentalisation-based therapy (20 weeks)
Trial: 34321051
Drug: Long-term mentalisation-based
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term mentalisation-based therapy (14 months)
Trial: 37853163
Drug: Oral intubation
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intubation
Trial: 32495059
Drug: Intravitreal anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal anti-VEGF injection (bevacizumab or ranibizumab)
Trial: 32495059
Drug: Intravitreal anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal anti-VEGF injection (bevacizumab) in HTG
Trial: 35081280
Drug: TNF inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitor
Trial: 33040012
Drug: Health-RESPECT intervention
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health-RESPECT intervention involving comprehensive geriatric assessment, individualised care plan, medication and rehabilitation management, periodic video-conference, and in-system assessment.
Trial: 34503290
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (two doses)
Trial: 36216679
Drug: BNT162b2 booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 booster dose
Trial: 33998206
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of TXA (15 mg/kg) 30 minutes before operation (Group A)
Trial: 33998206
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of TXA (1 g injected into the medullary cavity after proximal femur grooving) (Group B)
Trial: 33998206
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but can be inferred as no TXA administration)
Trial: 33414363
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavior therapy (TF-CBT)
Trial: 36316078
Drug: Complex multidisciplinary
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex multidisciplinary intervention to improve initial medication adherence (IMA)
Trial: 32304981
Drug: Intramuscular or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular or intranasal administration of naloxone
Trial: 32202124
Drug: Dry needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling combined with manual therapy (DN+MT)
Trial: 36533622
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment alone
Trial: 34529156
Drug: Nasal corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal corticosteroid (NC) therapy + normal saline solution (NSS) administered twice a day (Group 2)
Trial: 34529156
Drug: Nasal corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal corticosteroid (NC) therapy only (Group 1)
Trial: 37626292
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol
Trial: 34379922
Drug: Cabotegravir (CAB-LA)
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabotegravir (CAB-LA) 600 mg intramuscularly every 8 weeks
Trial: 34379922
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) daily
Trial: 36375487
Drug: Control (Proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Proton Pump Inhibitor - Lansoprazole)
Trial: 35677096
Drug: Routine drug
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drug therapy
Trial: 34314240
Drug: Transurethral Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral Water Vapor Therapy (TWVT)
Trial: 34257042
Drug: Budesonide prophylaxis
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide prophylaxis (3 mg PO daily at day +5 post‐AHCT till discharge)
Trial: 36611211
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition
Trial: 32085844
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (specifically amino acids)
Trial: 32783769
Drug: Essen group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essen group (control vaccine)
Trial: 34024173
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 × 150 mg caffeine daily for 10 days)
Trial: 34879822
Drug: Low mean
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low mean arterial pressure (L-MAP) group
Trial: 32616026
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of antibiotics at anesthesia induction (n = 73)
Trial: 33586174
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (no treatment)
Trial: 33010188
Drug: Ustekinumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (6 mg/kg intravenously at week 0, followed by 90 mg subcutaneously every 8 weeks)
Trial: 35412513
Drug: No-pill control
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-pill control (NPC)
Trial: 33713742
Drug: Cisplatin at
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at 40 mg/m²
Trial: 32321651
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (TRPMS)
Trial: 36889611
Drug: Therapeutic-dose enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose enoxaparin and therapeutic-dose apixaban
Trial: 34781363
Drug: Eltrombopag 50
RxNorm normalized name: eltrombopag 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 50 mg daily
Trial: 33611431
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy plus cTACE (arm A)
Trial: 32676980
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living
Trial: 32079557
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy
Trial: 34175857
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 0.3 mg/kg
Trial: 37093712
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg subcutaneously
Trial: 37059702
Drug: Perampanel 8
RxNorm normalized name: perampanel 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 8 mg/day
Trial: 35042057
Drug: Talus mobilization-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talus mobilization-based manual therapy (six sessions of anteroposterior talus mobilization)
Trial: 32922827
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (control group)
Trial: 32961410
Drug: Oxytocin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (24 IU intranasal)
Trial: 36455187
Drug: Decitabine (DAC)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine (DAC) 20 mg/m2/d days 1‐5
Trial: 36455187
Drug: Hydroxyurea (HY)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HY) 1‐4 g/d
Trial: 34331258
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 60 mg
Trial: 35526605
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg dose, oral)
Trial: 34167284
Drug: Conventional dressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dressing (CD) group - normal temperature boric acid solution wet dressing, 3 times a day
Trial: 33028661
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment of COVID-19 (specific details not provided)
Trial: 36376399
Drug: Ag NPs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ag NPs at 50 µg/mL
Trial: 36376399
Drug: Ag NPs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ag NPs at 250 µg/mL
Trial: 35470199
Drug: Open dialogue
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open dialogue about complementary and alternative medicine (OD‐CAM)
Trial: 35907370
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (40 ml)
Trial: 35907370
Drug: Placebo (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0.9%, 40 ml)
Trial: 36128889
Drug: B-vitamin intervention
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin intervention (combined folic acid 200 μg, vitamin B12 10 μg, vitamin B6 10 mg, riboflavin 5 mg)
Trial: 33266022
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (200,000 IU bolus at week 0 followed by 20,000 IU/day for 7 weeks)
Trial: 33266022
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D combined with infliximab (5 mg/kg at weeks 0, 2, and 6)
Trial: 32163420
Drug: Intravenous rehydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rehydration
Trial: 36419043
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Low-dose CT scans and 3D models printed before inexperienced surgeons performed surgeries
Trial: 36419043
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Standard-dose CT scans and 3D models printed before experienced surgeons performed surgeries
Trial: 36419043
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Standard-dose CT scans, operations performed by inexperienced surgeons
Trial: 36419043
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: Standard-dose CT scans, operations performed by experienced surgeons
Trial: 32012257
Drug: Family-Focused Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Focused Treatment for Adolescents (FFT-A)
Trial: 35749864
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily activities)
Trial: 34015241
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg three times per week
Trial: 36002117
Drug: 5,000 mg
RxNorm normalized name: garlic 5,000 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 mg ASA orally once daily from D 120 until parturition (group ASA1)
Trial: 37031887
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg twice daily)
Trial: 35932798
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in treatment plans after pneumonia
Trial: 34126053
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of RAS inhibition